Chong Kun Dang Receives MFDS Approval for Type 2 Diabetes Treatment 'Duvie S Tablets'
Chong Kun Dang announced on the 9th that its type 2 diabetes treatment drug, Dubies Jeong (active ingredients: lobeglitazone sulfate and sitagliptin), has received domestic product approval from the Ministry of Food and Drug Safety.
Dubies Jeong can be used for adult patients with type 2 diabetes who are suitable for combination therapy with lobeglitazone and sitagliptin. Dubies Jeong is scheduled to be launched in the domestic market in September.
Hot Picks Today
"Could I Also Receive 370 Billion Won?"... No Limit on 'Stock Manipulation Whistleblower Rewards' Starting the 26th
- Samsung Electronics Labor-Management Reach Agreement, General Strike Postponed... "Deficit-Business Unit Allocation Deferred for One Year"
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- "Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
Chong Kun Dang stated that Dubies Jeong is expected to provide a new treatment option for type 2 diabetes patients whose blood sugar is not controlled by combination therapy with sitagliptin and metformin, and to improve medication convenience.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
